Abstract-Nitroglycerin (GTN) tolerance was induced in vivo (rats) and in vitro (rat and human vessels). Electrochemical detection revealed that the incubation dose of GTN (5ϫ10 Ϫ6 mol/L) did not release NO or modify O 2 consumption when administered acutely. However, development of tolerance produced a decrease in both mitochondrial O 2 consumption and the K m for O 2 in animal and human vessels and endothelial cells in a noncompetitive action. GTN tolerance has been associated with impairment of GTN biotransformation through inhibition of aldehyde dehydrogenase (ALDH)-2, and with uncoupling of mitochondrial respiration. Feeding rats with mitochondrial-targeted antioxidants (mitoquinone [MQ]) and in vitro coincubation with MQ (10 Ϫ6 mol/L) or glutathione (GSH) ester (10 Ϫ4 mol/L) prevented tolerance and the effects of GTN on mitochondrial respiration and ALDH-2 activity. Biotransformation of GTN requires functionally active mitochondria and induces reactive oxygen species production and oxidative stress within this organelle, as it is inhibited by mitochondrial-targeted antioxidants and is absent in HUVEC 0 cells. Experiments analyzing complex I-dependent respiration demonstrate that its inhibition by GTN is prevented by mitochondrial-targeted antioxidants. Furthermore, in presence of succinate (10ϫ10 Ϫ3 mol/L), a complex II electron donor added to bypass complex I-dependent respiration, GTN-treated cells exhibited O 2 consumption rates similar to those of controls, thus suggesting that complex I was affected by GTN. We propose that, following prolonged treatment with GTN in addition to ALDH-2, complex I is a target for mitochondrially generated reactive oxygen species. Our data also suggest a role for mitochondrial-targeted antioxidants as therapeutic tools in the control of the tolerance that accompanies chronic nitrate use. ) have generally been attributed to its bioconversion into the relaxant agent nitric oxide (NO), which acts on the enzyme soluble guanylate cyclase (sGC). [1] [2] [3] However, most studies that support the existence of such a pathway have demonstrated increases of NO only when GTN concentrations considerably exceeded the plasma levels reached during clinical dosing. 4 Moreover, the involvement of other NO-related species in the actions of GTN when used at clinically relevant concentrations is also under debate. 5, 6 Different enzymes have been implicated in the bioconversion of GTN, in particular, glutathione S-transferases, 7 the cytochrome p450 system, 8 and xanthine oxidoreductase, 9 although the most recent evidence suggests a central role for mitochondrial aldehyde dehydrogenase (ALDH)-2. 10 -13 The medical use of GTN is limited by the development of tolerance, which occurs following prolonged administration or the application of high doses. This phenomenon has been related to various mechanisms, in particular, desensitization of sGC, 14 and, mainly, impairment of GTN biotransformation by inhibition of ALDH-2. 10 -12 These actions, like others associated with GTN, have been linked to an increase in the production of reactive oxygen species (ROS), 15 as well as mitochondrial dysfunction. 11 The present study confirms the theory that tolerance to GTN (both in vivo and in vitro) is related to the oxidative stress that leads to an inhibition of ALDH-2. Furthermore, through the use of mitochondrial antioxidants such as mitoquinone (MQ), 16, 17 or glutathione (GSH) ester, 18 we have confirmed the mitochondria to be the main location for the development of tolerance. Finally, we have identified mitochondrial complex I as a target at which the initial oxidative stress responsible for GTN tolerance takes place.
T he vasodilatory actions of nitroglycerin (glyceryl trinitrate [GTN] ) have generally been attributed to its bioconversion into the relaxant agent nitric oxide (NO), which acts on the enzyme soluble guanylate cyclase (sGC). [1] [2] [3] However, most studies that support the existence of such a pathway have demonstrated increases of NO only when GTN concentrations considerably exceeded the plasma levels reached during clinical dosing. 4 Moreover, the involvement of other NO-related species in the actions of GTN when used at clinically relevant concentrations is also under debate. 5, 6 Different enzymes have been implicated in the bioconversion of GTN, in particular, glutathione S-transferases, 7 the cytochrome p450 system, 8 and xanthine oxidoreductase, 9 although the most recent evidence suggests a central role for mitochondrial aldehyde dehydrogenase (ALDH)-2. 10 -13 The medical use of GTN is limited by the development of tolerance, which occurs following prolonged administration or the application of high doses. This phenomenon has been related to various mechanisms, in particular, desensitization of sGC, 14 and, mainly, impairment of GTN biotransformation by inhibition of ALDH-2. 10 -12 These actions, like others associated with GTN, have been linked to an increase in the production of reactive oxygen species (ROS), 15 as well as mitochondrial dysfunction. 11 The present study confirms the theory that tolerance to GTN (both in vivo and in vitro) is related to the oxidative stress that leads to an inhibition of ALDH-2. Furthermore, through the use of mitochondrial antioxidants such as mitoquinone (MQ), 16, 17 or glutathione (GSH) ester, 18 we have confirmed the mitochondria to be the main location for the development of tolerance. Finally, we have identified mitochondrial complex I as a target at which the initial oxidative stress responsible for GTN tolerance takes place.
Materials and Methods
Umbilical cords obtained from the Department of Gynaecology (Faculty of Medicine of Valencia) were cut into rings (5 To generate HUVEC 0 cells, 50 ng/mL ethidium bromide was added to the medium for 7 days to inhibit mitochondrial gene transcription and activity. 11 Pyruvate (110 mg/mL) and uridine (50 g/mL) were used as alternative energy and nucleotide sources. Lack of mitochondrial gene expression was evaluated by Western blot analysis for cytochrome c oxidase subunit I (Molecular Probes, Leiden, The Netherlands), and the absence of respiratory function was measured by analyzing mitochondrial oxygen (O 2 ) consumption.
All protocols complied with European Community guidelines for the use of experimental animals and were approved by the Ethics Committee of the University of Valencia.
Vascular Contractility Studies
Rings were suspended in an organ bath containing Krebs solution (37°C), as described previously. 6 GTN tolerance was induced in vitro by incubating rings for 3 hours with GTN (5ϫ10 Ϫ6 mol/L). Rings from the in vivo nitrate-tolerance experiments were obtained from rats that had been allowed free access for 14 days to tap water with or without MQ or triphenylphosphonium (TPP) (5ϫ10 Ϫ4 mol/L) 20 and that had been treated with a GTN patch for the last 3 days. 15 All of these parameters were selected from preliminary experiments and were similar to those used by other authors. 15, 21, 22 Relaxation-response curves were obtained by adding cumulative concentrations of GTN (10 Ϫ10 to 10 Ϫ4 mol/L) or DETA-NO (10 Ϫ8 to 10 Ϫ4 mol/L). Some experiments were performed in aortic denudated rings, and, when necessary, either MQ (10 Ϫ6 mol/L) or GSH ester (10 Ϫ4 mol/L) was added 1 hour before the 3-hour GTN incubation period and maintained thereafter. In preliminary experiments the lipophilic cation linker TPP (5ϫ10 Ϫ6 mol/L), responsible for targeting MQ to mitochondria, showed no effect on vascular responses. When necessary, experiments were performed in the presence of non-mitochondrial-targeted antioxidants such as uric acid (UA) (10 Ϫ4 
ALDH Activity
The activity of ALDH-2 in homogenates of aortic rings was determined by measuring the conversion of propionaldehyde to propionic acid 11 and was expressed as the mean rate of absorbance (0.0125 A 340 was equivalent to 1 nmol/mg per minute).
Measurements of O 2 Consumption and NO Production
The aorta from 2 animals (100Ϯ1.04 mg wet weight) or human umbilical arteries or veins (196Ϯ2.3 or 199Ϯ3.6 mg wet weight, respectively) were cut into rings and resuspended in Krebs solution. Ϫ3 mol/L). Induction of GTN tolerance (in vivo or in vitro) and the use of mitochondrial and non-mitochondrialtargeted antioxidants were similar to those described in the vascular reactivity studies. When administered acutely, the dose of GTN used (5ϫ10 Ϫ6 mol/L) had no effect on mitochondrial O 2 consumption, despite producing maximal relaxations of vascular rings. The aforementioned tissues were then placed in a gas-tight chamber, and O 2 consumption was measured with a Clark-type O 2 electrode (Rank Brothers, Bottisham, UK). 6 Sodium cyanide (10 Ϫ3 mol/L) confirmed that O 2 consumption was mainly mitochondrial. Measurements were collected using the data-acquisition device Duo.18 (WPI, Stevenage, UK). A hyperbolic function was used to describe the relationship between O 2 concentration and the rate of O 2 consumption (VO 2 ). The maximal rate of O 2 consumption (VO 2max ) and the apparent O 2 affinity Michaelis-Menten constant (K m ) (10 Ϫ6 mol/L) were calculated according to their analogy with the Michaelis-Menten constant. Trypan blue exclusion test revealed no changes in cell viability.
NO concentration in the cell medium was monitored throughout the 3-hour incubation period with GTN by means of an NO electrode (ISO-NOP; WPI, Stevenage, UK) as described previously. 23 The NO donor DETA-NO (10 Ϫ5 mol/L) was added at the end of each experiment as an internal control. Changes in intracellular NO were also evaluated by incubating cells with the fluorescent probe diaminodifluorofluorescein diacetate (DAF-FM DA) (1ϫ10 Ϫ6 mol/L). Thereafter, the medium was changed to HBSS, supplemented with
, and DAF-FM, incubated for 30 minutes and measured using a Fluoroskan plate reader (TL, Franklin, Mass). cGMP levels were measured with the Biomol assay kit (Plymouth Meeting, Pa).
Measurement of ROS Production, GSH Content, and Complex I Activity
Two methods were used to evaluate ROS. Total ROS production was assessed following incubation (30 minutes) with the fluorescent probe 2Ј,7Ј-dichlorodihydrofluorescein diacetate (DCFH-DA) (5ϫ10 Ϫ6 mol/L), as described elsewhere. 24 Quantitative assessment of hydrogen peroxide (H 2 O 2 ) was performed with the Amplex Red H 2 O 2 /Peroxidase Assay kit (Molecular Probes, Eugene, Ore). 25, 26 GSH content was assessed following incubation (30 minutes) with the fluorescent probe monochlorobimane (MCB) (40ϫ10 Ϫ6 mol/L). GSH levels were also measured by confocal microscopy (Leica, Heidelberg, Germany), following incubation (30 minutes) with 5-chloromethylfluorescein diacetate (CMFDA) (1ϫ10 Ϫ6 mol/L). The ratio oxidized glutathione (GSSG)/GSH was calculated as previously described. 27 Proteins were determined using the BCA protein assay kit (Pierce, Rockford, Ill).
The activity of mitochondrial complex I was assessed by calculating the NADH oxidation rate. 28 Briefly, a cellular homogenate (20 L, 0.3 mg) was added to 1 mL of potassium phosphate buffer (10 Ϫ2 mol/L) containing NADH (10 Ϫ4 mol/L) at 37°C. Basal absorbance (340 nm) was recorded for 1 minute, and 5 L of ubiquinone (10 Ϫ2 mol/L) was then added, and the rate of NADH oxidation (taken as complex I activity) over 2 minutes was measured. The NADH oxidation rate was calculated from the time-dependent decrease in the slope of absorbance using an extinction coefficient for NADH of 6.81ϫ10
Ϫ3 mol/L cm Ϫ1 at 340 nm. Isolated complex I-dependent respiration was evaluated in digitonin permeabilized cells in the presence of the complex I substrates malate (0.4ϫ10 Ϫ3 mol/L) and glutamate (3ϫ10 Ϫ2 mol/L), the complex II substrate succinate (10 Ϫ2 mol/L), or the complex I inhibitor rotenone (6ϫ10 Ϫ6 mol/L). 29 ) . The GTN used is a clinically used preparation (Solinitrina, Allmirall, Barcelona, Spain). Patches of GTN were from Schering-Plough (Madrid, Spain). Na-pyruvate was from GIBCO-BRL (Gaithersburg, Md). Ethidium bromide was from SERVA (Heidelberg, Germany). HBSS and medium 199 were from Cambrex (Verviers, Belgium). DETA-NO was from Alexis (San Diego, Calif). DAF-FM, and DCFH-DA were from Calbiochem (San Diego, Calif). MCB and CMFDA were from Molecular Probes (Eugene, Ore). MQ was synthesized according to the published method. 30 GSH ester was prepared as previously described. 31
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Data Analysis
Unless stated otherwise all values are meanϮSEM of at least 5 experiments. Statistical analysis was performed with 1-way ANOVA with post hoc corrections, followed by the Student t test for unpaired samples (GraphPad Software). Significance was defined as PϽ0.05.
Results
Tolerance to GTN Vasorelaxation Figure 1 shows dose-dependent relaxation curves by GTN (10 Ϫ10 to 10 Ϫ4 mol/L) in precontracted (Phe 10 Ϫ6 mol/L) rings. Figure 1A represents results from rat aorta in which tolerance was induced in vivo, and Figure 1B and 1C show results from rat aorta and human umbilical artery and vein in which tolerance was induced in vitro. GTN, although they continued to differ from those of controls (91.6Ϯ2% of controls, PϽ0.05 versus both).
Treatment with MQ (in vivo or in vitro) or GSH ester (in vitro) during the induction of tolerance restored the acute vasorelaxant effects of GTN, suggesting that mitochondrial ROS were involved in the development of GTN tolerance. Addition of non-mitochondrial-targeted antioxidants (UA, Eb, and TP) following the in vitro induction of tolerance only partially restored the acute effects of GTN ( Figure 1C) . pEC 50 values with DETA-NO (10 Ϫ8 to 10 Ϫ4 mol/L) were similar in controls (6.06Ϯ0.07) and GTN-tolerant (5.96Ϯ0.05) aortas. Incubation with DETA-NO (5ϫ10 Ϫ6 mol/L; 3 hours) did not induce tolerance to the effects of the GTN (7.98Ϯ0.07) administered later.
GTN Biotransformation
ALDH activity was significantly (PϽ0.001) diminished in GTN-tolerant aortas when compared with that of controls (1.1Ϯ0.1 vs 2.8Ϯ0.2 nmol/mg per minute, respectively).
Presence of MQ or GSH ester during the in vitro induction of GTN tolerance prevented such a decrease (2.7Ϯ0.2 and 2.5Ϯ0.2 nmol/mg per minute, respectively). Figure 2 and Table 2 show that the rate of O 2 consumption, the apparent K m for O 2 , and VO 2max decreased in vessels in which GTN tolerance was induced in vivo (Figure 2A ) or in vitro ( Figure 2B ). Treatment with MQ (in vivo or in vitro) or GSH ester (in vitro) during the induction of tolerance prevented these inhibitory effects of GTN. Following the in vitro induction of tolerance, addition of non-mitochondrialtargeted antioxidants partially (PϽ0.05) restored the inhibitory effects of GTN ( Table 2) . Presence of the NO scavenger hemoglobin (10 Ϫ5 mol/L) or the sGC inhibitor ODQ (5ϫ10 Ϫ6 mol/L) did not modify the effects of GTN on O 2 consumption (data not shown). Figure 2C shows representative traces of the electrochemical detection of NO in a medium containing HUVECs. 
Mitochondrial O 2 Consumption
Addition of GTN (5ϫ10
Ϫ6 mol/L) did not induce any NO signal, whereas a robust increase was noted following DETA-NO (10 Ϫ5 mol/L). Similar results were obtained with the NO-sensitive fluorescent probe DAF-FM (data not shown).
Role of Mitochondria in GTN-Induced cGMP Production
To confirm the role of functioning mitochondria in GTN bioactivity, we created HUVEC 0 cells and considered the absence of cytochrome c oxidase subunit I as an index ( Figure  3A ). These cells were associated with a 99% reduction in O 2 
ROS Production and GSH Levels
Preincubation of HUVECs with GTN significantly increased the fluorescence of DCFH-DA, indicating an augmented production of ROS ( Figure 4A) . A similar increase was observed when the effects of GTN preincubation were evaluated by confocal microscopy ( Figure 4B ). Incubation with GTN also increased H 2 O 2 ( Figure 4C ). In all cases, coincubation with MQ and GSH ester reversed the effects of GTN. Similar results were obtained in HUAECs (data not shown). Neither incubation of HUVEC 0 cells with GTN nor acute administration of GTN in both HUVECs and HUVEC 0 cells produced any increase in ROS-related fluorescence. Pretreatment with GTN produced increases in H 2 O 2 in aortic rings with and without endothelium ( Figure 4D ), and coincubation with MQ or GSH ester prevented such an increase (data not shown). Although the removal of the endothelium reduced the level of fluorescence, the production of ROS continued to be substantial, thus suggesting that both muscle and endothelial cells are capable of generating ROS following incubation with GTN.
Oxidative stress is related to both an increase in ROS production and a decrease in antioxidant content. As shown in Figure 5A , preincubation of HUVECs with GTN significantly decreased the fluorescence of MCB, indicating a reduction in GSH levels. A similar diminution in CMFDA fluorescence was observed when the effects of GTN were evaluated by confocal microscopy ( Figure 5B ). Treatment with MQ reversed these effects, and, as expected, GSH ester boosted the levels of the fluorescence signal. Figure 5C shows how incubation with GTN increased the GSSG:GSH ratio, an index of oxidative stress, whereas MQ and GSH ester prevented this effect. Figure 6A shows the inhibitory effects of preincubation with GTN on mitochondrial complex I activity, as calculated from the rate of NADH oxidation in HUVECs. Coincubation with either MQ or GSH ester reversed this effect. The specificity of the action of GTN was further characterized through an alternative method involving cells permeabilized with digitonin and measurement of isolated complex I-dependent respiration. Figure  6B shows that HUVECs respiring on the complex I substrates malate (0.4ϫ10 Ϫ3 mol/L) and glutamate (30ϫ10 Ϫ3 mol/L) were inhibited by nearly 90% with the complex I inhibitor rotenone (6ϫ10 Ϫ6 mol/L). Cells incubated with GTN respired very poorly with malate and glutamate, whereas rotenone-sensitive respiration did not differ to that observed in the absence of the inhibitor. When succinate (10ϫ10 Ϫ3 mol/L), a complex II electron donor, was added to bypass complex I-dependent respiration, GTNtreated cells exhibited O 2 consumption rates similar to those of controls, suggesting that complex I was the main target of GTN preincubation. Coincubation with MQ or GSH ester prevented the effects of GTN preincubation on the levels of complex I-dependent respiration. methods confirm this hypothesis, because incubation with GTN increased the release of ROS in vascular cells and tissues. The mitochondria seems the origin of said ROS production, as they were absent in HUVEC 0 cells, whereas treatment with MQ and GSH ester reversed the increase in both ROS and oxidative stress that followed incubation with GTN. It is important to highlight the important contribution of vascular muscle cells to this genesis of ROS, as demonstrated by the maintenance of a substantial production in endothelium-denudated vessels.
GTN Impairs Mitochondrial O 2 Consumption by Inhibiting Complex I: Reversal by Mitochondrial-Targeted Antioxidants
The subsequent oxidative stress and complex I impairment following long-term treatment with GTN could inactivate ALDH-2 or inhibit the ALDH-2 repair system, both of which result in the impairment of GTN bioactivation. In addition, a potential interaction with superoxide may decrease the bioavailability of the vasodilator released following GTN bioactivation. ROS are highly toxic to various sites of mitochondrial respiratory chain, and inhibition of complex I would seem to be the most likely consequence. 22 We demonstrate that GTN tolerance is accompanied by a marked reduction in NADH oxidation, indicative of a reduction in complex I activity and prevented by mitochondrial-targeted antioxidants. Further experiments analyzing isolated complex I-dependent respiration in permeabilized HUVECs demonstrated that in the presence of succinate, a complex II electron donor added to bypass complex I-dependent respiration, GTN-treated cells exhibited O 2 consumption rates similar to those of controls, thus confirming that continuous exposure to GTN mainly affects complex I. Again, MQ and GSH ester prevented the effects of GTN, highlighting ROSmediated damage in complex I as the likely cause of the respiration deficiency.
In conclusion, the present study confirms that prolonged exposure to GTN induces oxidative stress and highlights the mitochondria as both the source and target of ROS. In addition, we propose that the activity of mitochondrial complex I is diminished following continuous incubation with GTN. Our data provide fresh insight into the mechanisms responsible for nitrate tolerance, suggesting a potential role for mitochondrial-targeted antioxidants as a therapeutic tool in the prevention or control of the tolerance that accompanies the chronic use of GTN in patients. 
